<生产厂家价格>

蛋白激酶仰制剂KT5720

蛋白激酶仰制剂KT5720用途

KT5720 是一种能透过细胞的、有效的、特异性的、可逆的、ATP 竞争性的蛋白酶 K (PKA) 的抑制剂,其 Ki 值为 60 nM。

蛋白激酶仰制剂KT5720名称

[ CAS 号 ]:
108068-98-0

[ 中文名 ]:
蛋白激酶仰制剂KT5720

[ 英文名 ]:
KT5720

[英文别名 ]:

MFCD00132118

蛋白激酶仰制剂KT5720生物活性

[ 描述 ]:

KT5720 是一种能透过细胞的、有效的、特异性的、可逆的、ATP 竞争性的蛋白酶 K (PKA) 的抑制剂,其 Ki 值为 60 nM。

[ 相关类别 ]:

研究领域 >> 内分泌

信号通路 >> 蛋白酪氨酸激酶 >> PKA

信号通路 >> 干细胞及 Wnt 通路 >> PKA

研究领域 >> 代谢疾病

[ 靶点 ]

Ki: 60 nM (PKA)[1][2].

[参考文献]

[1]. Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.

[2]. Murray A, et al. Pharmacological PKA inhibition: all may not be what it seems. Sci Signal. 2008 Jun 3;1(22):re4.

蛋白激酶仰制剂KT5720物理化学性质

[ 密度 ]:
1.49g/cm3

[ 沸点 ]:
715ºC at 760mmHg

[ 分子式 ]:
C₃₂H₃₁N₃O₅

[ 分子量 ]:
537.60600

[ 闪点 ]:
386.2ºC

[ 精确质量 ]:
537.22600

[ PSA ]:
94.72000

[ LogP ]:
5.93440

[ 蒸汽压 ]:
1.88E-21mmHg at 25°C

[ 折射率 ]:
1.752

[ 储存条件 ]:
-20°C，密闭，干燥

蛋白激酶仰制剂KT5720安全信息

[ 危害码 (欧洲) ]:
Xi

[ 风险声明 (欧洲) ]:
R36/38

[ 安全声明 (欧洲) ]:
S26-S36

[ 危险品运输编码 ]:
NONH for all modes of transport

蛋白激酶仰制剂KT5720文献

Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2.

Biochem. Pharmacol. 96 , 306-14, (2015)

Metastasis is the major cause of death in cancer patients. Elevated expression of cyclooxygenase-2 (COX-2) is observed in many human cancers and over-production of downstream prostaglandins (PGs) has ...

Involvement of cAMP in nerve growth factor-triggered p35/Cdk5 activation and differentiation in PC12 cells.

Am. J. Physiol. Cell Physiol. 299 , C516-27, (2010)

The signaling mechanisms underlying cell differentiation have been extensively studied with the use of rat PC12 cells as a model system. Nerve growth factor (NGF) is a trophic factor inducing PC12 cel...

Prostaglandin potentiates 5-HT responses in stomach and ileum innervating visceral afferent sensory neurons.

Biochem. Biophys. Res. Commun. 456(1) , 167-72, (2015)

Gastrointestinal disorder is a common symptom induced by diverse pathophysiological conditions that include food tolerance, chemotherapy, and irradiation for therapy. Prostaglandin E2 (PGE2) level inc...

更多文献